Development of XBB 1.5 Monovalent Vaccine for Growing Sub Variant

Discussion on the development of a new XBB 1.5 monovalent vaccine targeting the widespread EG.5.1 variant, including spike protein differences and potential vaccine effectiveness. The chapter also mentions preliminary clinical trial data from Moderna's updated vaccine.